Los puntos clave no están disponibles para este artículo en este momento.
Research on IBDs has identified disrupted immune responses in the gastrointestinal mucosa and putative disruptions in the gut microbiome as causative agents. This work has led to better therapeutic control of IBDs with the use of various antiinflammatory agents.
John T. Chang (Wed,) studied this question.